Loading
A phase 3 trial in colorectal cancer, run by Fudan University, now recruiting.
Circulating Tumor DNA Methylation Guided Postoperative Adjuvant Chemotherapy for High-risk Stage II/III Colorectal Cancer is a phase 3, randomised interventional study registered as NCT05954078 by Fudan University, with a registry enrolment figure of 340 participants, started 2023-08-01 and due to reach its primary completion in 2026-06. Interventions recorded: mFOLFIRINOX adjuvant chemotherapy; mFOLFOX6/XELOX adjuvant chemotherapy. Conditions listed: High-risk Stage II Colorectal Cancer; Stage III Colorectal Cancer; Circulating Tumor DNA Methylation. Primary outcome: ctDNA clearance rate. Colorectal eligibility wording from the registry: "Patients who have been histopathologically diagnosed with colorectal adenocarcinoma;". Sites: China. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares MRD / molecular residual disease testing, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares MRD / molecular residual disease testing, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares MRD / molecular residual disease testing, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares MRD / molecular residual disease testing, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares MRD / molecular residual disease testing, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares MRD / molecular residual disease testing, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares MRD / molecular residual disease testing, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares MRD / molecular residual disease testing, Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/